Trastuzumab-induced toxic epidermal necrolysis in a Her-2-positive metastatic breast cancer patient-A rare case report

被引:0
|
作者
Ferdause, Jannatul [1 ]
Momtahena, Sura Jukrup [1 ]
Karim, Rubama [1 ]
Chowdhury, Aditi Paul [1 ]
Hossain, Nowshin Taslima [1 ]
Islam, Md Ariful [1 ]
Bin Habib, Maruf [2 ]
Kadir, A. K. M. Shafiul [3 ]
Haque, Md Ariful [4 ,5 ,6 ]
机构
[1] Ahsania Mission Canc & Gen Hosp, Dhaka, Bangladesh
[2] Ahsania Mission Med Coll, Dept Med, Dhaka, Bangladesh
[3] Quest Bangladesh Biomed Res Ctr, Dhaka, Bangladesh
[4] Atish Dipankar Univ Sci & Technol, Dept Publ Hlth, Dhaka, Bangladesh
[5] Voice Doctors Res Sch, Dhaka, Bangladesh
[6] Kunming Med Univ, Yanan Hosp, Dept Orthopaed Surg, Kunming, Yunnan, Peoples R China
来源
CLINICAL CASE REPORTS | 2024年 / 12卷 / 07期
关键词
anti HER-2 antibody; HER-2-positive breast cancer; Steven Johnson syndrome; toxic epidermal necrolysis; Trastuzumab; STEVENS-JOHNSON SYNDROME; GUIDELINES; MANAGEMENT; COMPLICATIONS; INVOLVEMENT;
D O I
10.1002/ccr3.9103
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Toxic Epidermal Necrolysis (TEN) is a rare, but potentially fatal mucocutaneous reaction, that may occur due to an immunologic response to certain medications. However, TEN triggered by Trastuzumab is extremely rare. Early diagnosis, recognition, and prompt cessation of the offending drugs and initiation of steroid therapy with supportive management are the most important actions for managing TEN. Although rare, it is important to be vigilant about this potential adverse reactions associated with trastuzumab to ensure patient safety and contribute to better outcomes.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Chemotherapy-induced toxic epidermal necrolysis in a patient with multiple myeloma, a case report and literature review
    Rui, X.
    Meidan, W.
    Gongqiang, W.
    Longyi, Z.
    Xiaoxia, W.
    Wei, C.
    Chenhui, W.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [32] Role of trastuzumab in the management of HER2-positive metastatic breast cancer
    Milani, Andrea
    Montemurro, Filippo
    Gioeni, Luisa
    Aglietta, Massimo
    Valabrega, Giorgio
    BREAST CANCER-TARGETS AND THERAPY, 2010, 2 : 93 - 109
  • [33] Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma: A Case Report and Literature Review
    Logan, Ian T.
    Zaman, Saman
    Hussein, Lama
    Perrett, Conal M.
    JOURNAL OF IMMUNOTHERAPY, 2020, 43 (03) : 89 - 92
  • [34] Paclitaxel, carboplatin, and trastuzumab in HER2-positive metastatic breast cancer
    Andrew D. Seidman
    Larry Norton
    Current Oncology Reports, 2005, 7 (1) : 9 - 11
  • [35] Trastuzumab in HER2-Positive Metastatic Gastric Cancer Profile Report
    Croxtall, Jamie D.
    McKeage, Kate
    BIODRUGS, 2011, 25 (04) : 257 - 259
  • [36] Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission
    Haq, R.
    Gulasingam, P.
    CURRENT ONCOLOGY, 2016, 23 (02) : 91 - 95
  • [37] Radiation recall dermatitis in HER 2 positive breast cancer patients triggered by trastuzumab: A rare case report and review of literature
    Ferdause, Jannatul
    Islam, Md Ariful
    Ahmed, Nusrat
    Kadir, A. K. M. Shafiul
    Haque, Md Ariful
    INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2024, 120
  • [38] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [39] Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
    Jeyakumar, Alwin
    Younis, Tallal
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [40] Very long response with trastuzumab for metastatic Her2-positive breast cancer
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (06) : 1002 - 1003